ClinicalTrials.gg

Osteoporosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,602 studies for Osteoporosis across more than 10 countries. 210 are recruiting or about to start. 1,024 of them are mainly about Osteoporosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Osteoporosis, Postmenopausal too: 1,811 studies, 226 open.

ClinicalTrials.gov finds 1,915 studies for Osteoporosis. How that becomes 1,602 here

This page counts the studies the registry files under Osteoporosis, and those it files under no condition that list Osteoporosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,915Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −209Filed under a narrower condition, counted on its own pageOsteoporosis, Postmenopausal 207
  3. −29List Osteoporosis as a condition, but the registry did not file them under itMost often written as “Osteopenia, Osteoporosis” (6), “Osteoporosis Fracture” (5), and “Osteoporosis Risk” (4). The registry filed them under other conditions only, most often Bone Diseases, Metabolic (10) and Fractures, Bone (5).
  4. −75Match it another way70 name it in the title and 5 in a keyword.
  5. 1,602The count on this page45 of them list Osteoporosis in their own words; the registry filed them under no condition.

Status

Completed
1,053
Status unknown
172
Recruiting
133
Terminated
66
Not yet recruiting
62
Active, not recruiting
54

Phase

Phase 3
207
Phase 4
171
Phase 2
169
Phase 1
114
Early Phase 1
7

Where

United States
481
Canada
120
France
97
China
87
Denmark
84
Italy
60

Who develops what

Add Osteoporosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 7 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Qilu Pharmaceutical, Shenzhen Salubris Pharmaceuticals and Mabwell (Shanghai) Bioscience here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DenosumabRecent, repeated
Evidence
  • NCT07062978 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Prolia®” · registered Jul 2025
  • NCT06804590 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · comparator · “Prolia®” · registered Dec 2024
  • NCT06504966 · Xentria, Inc. · Phase 3 · background · “Prolia®” · registered Jul 2024
  • NCT05345691 · Biocon Biologics UK Ltd · Phase 3 · comparator · “Prolia®” · registered Apr 2022
  • NCT05338086 · Fresenius Kabi · Phase 3 · comparator · “EU-Prolia” · registered Apr 2022
Amgen70% of its industry studiesUS: Amgen (FDA 2010) + 9 othersEU: Amgen (EMA 2010) + 29 others55 studies
AlendronateRecent, repeated
Evidence
  • NCT07028320 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Alendronate” · registered Jun 2025
  • NCT05397938 · CSPC Pharmaceutical Group Limited · Phase 2 · comparator · “Alendronate sodium” · registered May 2022
  • NCT02416271 · Eli Lilly and Company · Phase 4 · comparator · “Alendronate” · registered Apr 2015
  • NCT01631214 · Amgen · Phase 3 · background · “Alendronate” · registered May 2012
  • NCT01552122 · Merck & Co., Inc · Phase 3 · comparator · “Alendronate” · registered Mar 2012
Organon & Co.43% of its industry studiesUS: off-patent, 5 generics marketed22 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
QL1206☆ Track1 live phase-3 study: NCT07062978Qilu Pharmaceutical Co., Ltd.
QLG2128☆ Track1 live phase-3 study: NCT06898060Qilu Pharmaceutical Co., Ltd.

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.QL1206 · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aimvs DenosumabNCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® — primary endpoint: Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12 · 278 enrolled
  • May 2027 est.QLG2128 · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aim+ QLG2128 vs TeriparatideNCT06898060 To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture — primary endpoint: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 Week · 282 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Osteoporosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 2 open · SERMs 13 · Estrogens 10 · Aromatase inhibitors 7 · Statins 7

Coming up

76studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger. 9 (7%) take children under 18. 33 (25%) are for women only and 1 (1%) for men only; 36 (27%) take healthy volunteers.

Recruiting studies that take each age, of 133
AgeWomenMen
109 (7%)5 (4%)
1846 (35%)38 (29%)
3065 (49%)55 (41%)
4072 (54%)61 (46%)
50104 (78%)79 (59%)
65121 (91%)93 (70%)
75116 (87%)93 (70%)
85107 (80%)88 (66%)

Across all 1,602 studies, recruiting or not: 29% stop at 75 or younger and 19% at 65; 15% take children; 42% are for women only and 5% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Osteoporosis studies take

Of 65 phase 4 interventional studies under Osteoporosis, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo4–22 · 30 studies——
Phase 247 mo29–65 · 42 studies—60 mo34–65 · 33 studies
Phase 337 mo21–57 · 45 studies24 mo20–46 · 35 studies—
Phase 446 mo29–75 · 65 studies—47 mo31–71 · 55 studies
Interventional, no phase26 mo9–50 · 238 studies—22 mo8–49 · 219 studies
Observational51 mo24–97 · 126 studies—53 mo24–113 · 115 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,602. Browse all 1,602 → or search them.